Iovance's risks cluster around concentration and operations — one product family (lifileucel/Proleukin), one centralized manufacturing facility, one permanent CEO seat unfilled. The cash math also assumes burn keeps coming down.
↓ the brief below
From the 10-K · the candid capital warning
In order to complete the development of our current product candidates, and in order to affect our business plan, including expanding our own manufacturing facility, we anticipate that we will have to spend more than the funds currently available to us.
↳ Iovance itself flags: 'into 2028' is a projection, not a guarantee. Expanding the manufacturing facility and advancing the pipeline both cost money beyond what's on hand.
Source · 10-K · Item 7 — Liquidity and Capital Resources · FY2025 · Filed Feb 24, 2026
✦ Teach me
Why one factory is a real risk
Iovance has centralized manufacturing at the iCTC for cost and quality control. The upside: easier to scale, easier to ship from. The downside: if iCTC has a contamination event, FDA inspection issue, or natural disaster, every Amtagvi shipment stops at once. Q1 2026's revenue dip was already partly caused by planned maintenance. An unplanned event would be much worse — and the company has now expanded the facility specifically to address that.
Wall Street calls this
Single-site manufacturing risk
Concentration is efficient in normal times and devastating in bad ones. The cell therapy field has multiple examples of single-site failures dropping revenue 50%+ in a quarter.
The concentration · revenue mix
100%
two products
All revenue comes from just two products — Amtagvi (lifileucel) and Proleukin. Both made or distributed by one company. Pipeline expansion adds breadth in 2027-28, but for now the concentration is total.
We continue to recruit a new Chief Executive Officer. … In addition, the highly specialized nature of our cell therapy operations means that loss of senior commercial or manufacturing leadership would be especially disruptive.
↳ The CEO chair is open, and the type of leader Iovance needs is rare. This is named as a real risk by Iovance itself — not boilerplate.